Fount’s unique approach to health and performance optimization has garnered the attention of investors and clients alike. Its use of n=1 experimentation, combined with one-on-one coaching from experts in various fields, has proven highly effective for a wide range of clients, including executives, entrepreneurs, and new parents. The success of the Fount Pro program and the upcoming launch of additional products for sleep and women’s health demonstrate the company’s commitment to making tailored health and performance optimization accessible to a wider audience.

Fount’s proprietary data sets and AI expertise have also played a critical role in the company’s success. By combining these tools, Fount has been able to create uniquely effective and scalable products that address high-impact challenges. Its FlyKitt technology, for example, is the first true solution to jet lag, offering travelers the ability to travel anywhere in the world with minimal to no jet lag based on novel scientific insights into the role of inflammation in jet lag. With early results showing a 90% reduction in symptoms of premenstrual syndrome (PMS), Fount’s upcoming products for sleep and women’s health are likely to be equally groundbreaking.

The $12M Series A fundraise, led by Amity Ventures with participation from several other funds and angel investors, is a testament to Fount’s success and potential for growth. With this funding, Fount will be able to expand its world-class Fount Pro service and develop new products to solve high-impact challenges. The company’s experiment-driven approach, combined with its use of AI and proprietary data sets, positions it well for continued success in the health and performance optimization industry.